Immunotherapy in Melanoma

Keith Flaherty, MD, moderates this discussion with Rene Gonzalez, MD, Jason Luke, MD, FACP, and Jeffrey Weber, MD, PhD. The panel of experts in melanoma research and treatment talk about the most recent advances in the field, and provide perspective on how to apply the newest data to individualize treatment strategies.

View Now

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, and investigator at the Ludwig Center at Harvard, discusses the results of a 5-year follow-up analysis of survival outcomes of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

View Now